ArticleFrontiers in chemistry2026
A retrospective and in silico study on the augmentation of risperidone in the treatment of adolescent treatment-resistant depression: efficacy evaluation, adverse reaction analysis, and molecular mechanistic insights.
Article in Frontiers in chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Major depressive disorder (MDD) in adolescents remains a significant public health challenge. Treatment-resistant depression (TRD) affects a substantial proportion of cases and is associated with chronic symptoms, comorbidities, and elevated suicide risk. Standard treatments frequently show limited success, leading to off-label consideration of atypical antipsychotics as augmentation agents. Risperidone has shown promise in adults, but data in adolescents are limited. This retrospective study evaluates clinical outcomes of risperidone augmentation in adolescent TRD, complemented by Methods: Retrospective data from 50 adolescents (aged 12-18) with DSM-5 MDD and TRD (non-response to ≥2 antidepressants) were analyzed. Risperidone (0.25-2 mg/day) was added to ongoing antidepressants for ≥8 weeks. Efficacy was assessed via changes in CDRS-R and HAM-D scores, response (≥50% reduction), and remission rates. Adverse events were documented. In silico molecular docking and 200 ns MD simulations explored risperidone's interactions with selected targets (DRD2, 5-HT2AR, SERT, and NMDA) using available PDB structures. Results: Mean age was 15.4 years; 56% female. Depression scores improved: CDRS-R decreased from 64.3 to 38.9 (mean change -25.4 points), HAM-D from 23.6 to 12.1 (mean change -11.5 points). Response rates were 64% (CDRS-R) and 60% (HAM-D); remission rates were 40% and 36%, respectively. Baseline severity was associated with response (OR 1.22, p = 0.01). Common adverse events (mostly mild-moderate) included weight gain (24%), sedation (16%), and EPS (12%). Docking and MD simulations suggested favorable binding, particularly to DRD2 and 5-HT2AR. Conclusion: In this retrospective cohort, risperidone augmentation was associated with symptom improvement in adolescents with TRD and showed an acceptable short-term safety profile. In silico analyses suggest potential interactions with monoaminergic receptors that may contribute to its effects. These findings are hypothesis-generating and require confirmation in prospective randomized controlled trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.